DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Chlorothalonil

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CLD_ABCB11_6hr	Liver	Human	8647	ABCB11	Gain	20.0 μM
CLD_ABCG2_6hr	Liver	Human	9429	ABCG2	Gain	20.0 μM
CLD_CYP1A2_6hr	Liver	Human	1544	CYP1A2	Gain	34.03 μM
CLD_SULT2A_6hr	Liver	Human	6822	SULT2A1	Gain	33.89 μM
CLD_CYP2B6_48hr	Liver	Human	1555	CYP2B6	Gain	0.0 μM
CLD_CYP3A4_48hr	Liver	Human	1576	CYP3A4	Gain	0.0 μM
LTEA_HepaRG_ABCB11	Liver	Human	8647	ABCB11	Inhibitory	38.59 μM
LTEA_HepaRG_ALPP	Liver	Human	250	ALPP	Inhibitory	1.27 μM
LTEA_HepaRG_BAX	Liver	Human	581	BAX	Activatory	23.94 μM
LTEA_HepaRG_CAT	Liver	Human	847	CAT	Inhibitory	65.66 μM
LTEA_HepaRG_CCND1	Liver	Human	595	CCND1	Activatory	19.33 μM
LTEA_HepaRG_CFLAR	Liver	Human	8837	CFLAR	Activatory	50.0 μM
LTEA_HepaRG_CYP2C8	Liver	Human	1558	CYP2C8	Inhibitory	50.0 μM
LTEA_HepaRG_CYP2E1	Liver	Human	1571	CYP2E1	Activatory	66.12 μM
LTEA_HepaRG_CYP3A4	Liver	Human	1576	CYP3A4	Activatory	21.87 μM
LTEA_HepaRG_CYP3A7	Liver	Human	1551	CYP3A7	Activatory	50.0 μM
LTEA_HepaRG_CYP4A11	Liver	Human	1579	CYP4A11	Activatory	50.0 μM
LTEA_HepaRG_DDIT3	Liver	Human	1649	DDIT3	Inhibitory	21.92 μM
LTEA_HepaRG_FABP1	Liver	Human	2168	FABP1	Activatory	77.68 μM
LTEA_HepaRG_FASN	Liver	Human	2194	FASN	Inhibitory	35.53 μM
LTEA_HepaRG_FMO3	Liver	Human	2328	FMO3	Inhibitory	36.59 μM
LTEA_HepaRG_FOXO1	Liver	Human	2308	FOXO1	Inhibitory	23.15 μM
LTEA_HepaRG_FOXO3	Liver	Human	2309	FOXO3	Inhibitory	20.04 μM
LTEA_HepaRG_GSTA2	Liver	Human	2939	GSTA2	Inhibitory	33.96 μM
LTEA_HepaRG_GSTM3	Liver	Human	2947	GSTM3	Inhibitory	50.0 μM
LTEA_HepaRG_HSPA1A	Liver	Human	3303	HSPA1A	Inhibitory	17.34 μM
LTEA_HepaRG_LIPC	Liver	Human	3990	LIPC	Inhibitory	50.0 μM
LTEA_HepaRG_LPL	Liver	Human	4023	LPL	Activatory	17.98 μM
LTEA_HepaRG_MIR122	Liver	Human	406906	MIR122	Inhibitory	90.88 μM
LTEA_HepaRG_MMP10	Liver	Human	4319	MMP10	Activatory	20.2 μM
LTEA_HepaRG_MMP3	Liver	Human	4314	MMP3	Inhibitory	20.97 μM
LTEA_HepaRG_MYC	Liver	Human	4609	MYC	Activatory	50.0 μM
LTEA_HepaRG_PDK4	Liver	Human	5166	PDK4	Activatory	75.63 μM
LTEA_HepaRG_PTEN	Liver	Human	5728	PTEN	Inhibitory	68.75 μM
LTEA_HepaRG_SLC22A1	Liver	Human	6580	SLC22A1	Inhibitory	61.51 μM
LTEA_HepaRG_THRSP	Liver	Human	7069	THRSP	Activatory	18.3 μM
LTEA_HepaRG_TIMP1	Liver	Human	7076	TIMP1	Inhibitory	23.91 μM
LTEA_HepaRG_XBP1	Liver	Human	7494	XBP1	Inhibitory	82.27 μM
LTEA_HepaRG_SLC10A1	Liver	Human	6554	SLC10A1	Inhibitory	27.83 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
ATG_DR5_RAR_CIS	Liver	Human	5914\|5915\|5916	RARA\|RARB\|RARG	Inhibitory	0.17 μM
ATG_NRF2_ARE_CIS	Liver	Human	4780	NFE2L2	Activatory	0.1 μM
ATG_Oct_MLP_CIS	Liver	Human	5451	POU2F1	Activatory	0.14 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	0.12 μM
ATG_VDRE_CIS	Liver	Human	7421	VDR	Inhibitory	0.27 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	0.32 μM
BSK_3C_Eselectin	Vascular	Human	6401	SELE	Inhibitory	1.46 μM
BSK_3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	0.14 μM
BSK_3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	0.15 μM
BSK_3C_TissueFactor	Vascular	Human	2152	F3	Inhibitory	1.37 μM
BSK_3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	1.06 μM
BSK_4H_MCP1	Vascular	Human	6347	CCL2	Inhibitory	1.48 μM
BSK_4H_Pselectin	Vascular	Human	6403	SELP	Inhibitory	0.91 μM
BSK_4H_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	1.16 μM
BSK_4H_VEGFRII	Vascular	Human	3791	KDR	Inhibitory	1.44 μM
BSK_CASM3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	20.0 μM
BSK_hDFCGF_CollagenIII	Skin	Human	1281	COL3A1	Inhibitory	0.15 μM
BSK_hDFCGF_IL8	Skin	Human	3576	CXCL8	Inhibitory	1.1 μM
BSK_hDFCGF_IP10	Skin	Human	3627	CXCL10	Inhibitory	0.15 μM
BSK_hDFCGF_MCSF	Skin	Human	1435	CSF1	Inhibitory	1.11 μM
BSK_hDFCGF_MIG	Skin	Human	4283	CXCL9	Inhibitory	0.15 μM
BSK_hDFCGF_MMP1	Skin	Human	4312	MMP1	Inhibitory	0.99 μM
BSK_hDFCGF_PAI1	Skin	Human	5054	SERPINE1	Inhibitory	0.62 μM
BSK_hDFCGF_VCAM1	Skin	Human	7412	VCAM1	Inhibitory	1.08 μM
BSK_KF3CT_ICAM1	Skin	Human	3383	ICAM1	Inhibitory	0.79 μM
BSK_KF3CT_IL1a	Skin	Human	3552	IL1A	Inhibitory	1.5 μM
BSK_KF3CT_IP10	Skin	Human	3627	CXCL10	Inhibitory	0.58 μM
BSK_KF3CT_MMP9	Skin	Human	4318	MMP9	Inhibitory	1.23 μM
BSK_KF3CT_TGFb1	Skin	Human	7040	TGFB1	Inhibitory	1.32 μM
BSK_LPS_CD40	Vascular	Human	958	CD40	Inhibitory	0.13 μM
BSK_LPS_Eselectin	Vascular	Human	6401	SELE	Inhibitory	0.76 μM
BSK_LPS_IL1a	Vascular	Human	3552	IL1A	Inhibitory	0.94 μM
BSK_LPS_IL8	Vascular	Human	3576	CXCL8	Inhibitory	1.2 μM
BSK_LPS_MCP1	Vascular	Human	6347	CCL2	Inhibitory	1.15 μM
BSK_LPS_MCSF	Vascular	Human	1435	CSF1	Inhibitory	0.92 μM
BSK_LPS_PGE2	Vascular	Human	5732	PTGER2	Inhibitory	0.15 μM
BSK_LPS_TissueFactor	Vascular	Human	2152	F3	Inhibitory	0.33 μM
BSK_LPS_TNFa	Vascular	Human	7124	TNF	Inhibitory	0.13 μM
BSK_LPS_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	0.77 μM
BSK_SAg_CD38	Vascular	Human	952	CD38	Inhibitory	0.95 μM
BSK_SAg_CD40	Vascular	Human	958	CD40	Inhibitory	0.18 μM
BSK_SAg_CD69	Vascular	Human	969	CD69	Inhibitory	1.35 μM
BSK_SAg_Eselectin	Vascular	Human	6401	SELE	Inhibitory	0.96 μM
NVS_ADME_hCYP19A1		Human	1588	CYP19A1	Loss	0.19 μM
NVS_ADME_hCYP1A2		Human	1544	CYP1A2	Loss	0.41 μM
NVS_ADME_hCYP2C8		Human	1558	CYP2C8	Loss	0.21 μM
NVS_ADME_hCYP3A4		Human	1576	CYP3A4	Loss	0.3 μM
NVS_ADME_rCYP3A1		Rat	25642	Cyp3a23-3a1	Loss	1.11 μM
NVS_ADME_rCYP3A2		Rat	266682	Cyp3a2	Loss	0.24 μM
NVS_ENZ_hCK2a2b2		Human	1457	CSNK2A1	Loss	33.57 μM
NVS_ENZ_hDUSP3		Human	1845	DUSP3	Loss	17.67 μM
NVS_ENZ_hGSK3b		Human	2932	GSK3B	Loss	25.0 μM
NVS_ENZ_hPDE5		Human	8654	PDE5A	Loss	31.84 μM
NVS_ENZ_hPI3Ka		Human	5290	PIK3CA	Loss	33.13 μM
NVS_ENZ_hPTPN11		Human	5781	PTPN11	Loss	39.99 μM
NVS_ENZ_hSGK1		Human	6446	SGK1	Loss	19.84 μM
NVS_ENZ_hVEGFR3		Human	2324	FLT4	Loss	38.66 μM
NVS_ENZ_rACFSKBinding	Brain	Rat	64532	Adcy5	Loss	25.0 μM
NVS_NR_hGR		Human	2908	NR3C1	Loss	0.18 μM
NVS_NR_hPPARg		Human	5468	PPARG	Loss	0.54 μM
NVS_NR_hRARa_Agonist		Human	5914	RARA	Gain	36.9 μM
NVS_NR_hTRa_Antagonist		Human	7067	THRA	Loss	40.49 μM
CCTE_GLTED_hDIO1		Human	1733	DIO1	Loss	30.08 μM
CCTE_GLTED_hDIO3		Human	1735	DIO3	Loss	0.4 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.92 μM
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881	Breast	Human	367	AR	Loss	1.0 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	0.99 μM
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2	Breast	Human	2099	ESR1	Loss	70.78 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	0.65 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.32 μM
TOX21_VDR_BLA_Antagonist_ratio	Kidney	Human	1591\|7421	CYP24A1\|VDR	Loss	0.76 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	1.22 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	36.3 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	31.1 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	1.06 μM
TOX21_AChE_Antagonist		Human	43	ACHE	Loss	24.8 μM
TOX21_AR_BLA_Agonist_ratio	Kidney	Human	367	AR	Gain	62.57 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.95 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	1.05 μM
TOX21_ELG1_LUC_Agonist	Kidney	Human	79915	ATAD5	Gain	0.92 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	22.67 μM
TOX21_ERa_BLA_Antagonist_ratio	Kidney	Human	2099	ESR1	Loss	30.52 μM
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2	Breast	Human	2099	ESR1	Loss	48.9 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	33.91 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	0.56 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.19 μM
TOX21_VDR_BLA_Antagonist_ratio	Kidney	Human	1591\|7421	CYP24A1\|VDR	Loss	0.92 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	1.43 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2	Breast	Human	2099	ESR1	Loss	18.35 μM
TOX21_AChE_Colorimetric_Antagonist	Bone	Human	43	ACHE	Loss	17.63 μM
TOX21_SBE_BLA_Antagonist_ratio	Kidney	Human	4086	SMAD1	Loss	1.46 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	1.3 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	24.79 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	1.07 μM
TOX21_AChE_Antagonist		Human	43	ACHE	Loss	37.56 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	0.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	0.0 μM
OT_AR_ARSRC1_0480	Kidney	Human	367\|6714	AR\|SRC	Gain	18.63 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.34 μM
OT_NURR1_NURR1RXRa_0480	Kidney	Human	4929\|6256	NR4A2\|RXRA	Gain	0.08 μM
TOX21_HSE_BLA_Agonist_ratio	Cervix	Human	3297	HSF1	Gain	18.25 μM
TOX21_PPARd_BLA_Antagonist_ratio	Kidney	Human	5467	PPARD	Loss	1.29 μM
TOX21_PPARg_BLA_Antagonist_ratio	Kidney	Human	5468	PPARG	Loss	1.16 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	77.47 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	1.12 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	0.94 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	30.39 μM
TOX21_PPARd_BLA_Agonist_ratio	Kidney	Human	5467	PPARD	Gain	30.57 μM
TOX21_PPARd_BLA_Antagonist_ratio	Kidney	Human	5467	PPARD	Loss	1.13 μM
TOX21_PPARg_BLA_Antagonist_ratio	Kidney	Human	5468	PPARG	Loss	1.03 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	0.81 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	1.11 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	85.37 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	1.35 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.